Bolt Biotherapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M | $231.0K |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $28.5M | $57.5M | $61.5M | $73.1M | $75.7M | $40.4M |
| SG&A Expense | $13.8M | $18.5M | $22.5M | $22.9M | $18.4M | $9.1M |
| Operating Income | $-36.1M | $-73.0M | $-76.2M | $-90.3M | $-92.8M | $-49.2M |
| Operating Margin | -469.3% | -949.9% | -967.4% | -1,576.6% | -7,364.1% | -21,290.9% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-33.4M | $-63.1M | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-33.4M | $-63.1M | $-69.2M | $-88.1M | $-98.6M | $-60.7M |
| Net Margin | -433.7% | -820.8% | -878.6% | -1,537.8% | -7,824.7% | -26,289.2% |
| EPS (Basic) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | $-1.70 |
| EPS (Diluted) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | $-1.70 |
| Shares Outstanding (Basic) | 1.9M | 1.9M | 37.8M | 37.4M | 33.2M | 33.8M |
| Shares Outstanding (Diluted) | 1.9M | 1.9M | 37.8M | 37.4M | 33.2M | 33.8M |
| Dividends Per Share | — | — | — | — | — | — |